CASI Pharmaceuticals (CASIF) Equity Ratio (2021 - 2025)

CASI Pharmaceuticals has reported Equity Ratio for 5 years, with the latest figure at 1.45 in Q4 2025.

• For the quarter ending Q4 2025, Equity Ratio fell 4314.73% year-over-year to 1.45; the trailing twelve-month figure through Dec 2025 stood at 1.45 (down 4314.73% YoY), and the FY2025 full-year result was 1.45, down 4314.73% from the prior year.
• Equity Ratio for Q4 2025 stood at 1.45, down from 0.03 in the prior quarter.
• The five-year high for Equity Ratio was 175947.42 in Q2 2024, with the low at 1.45 in Q4 2025.
• Historically, Equity Ratio has averaged 25135.38 across 5 years, with a median of 0.32 in 2023.
• Annual changes were most pronounced in 2022 — Equity Ratio decreased 24.19% — and 2025, when it sank 4314.73%.
• CASI Pharmaceuticals' Equity Ratio stood at 0.61 in 2021, then decreased by 24.19% to 0.46 in 2022, then slumped by 30.69% to 0.32 in 2023, then tumbled by 89.26% to 0.03 in 2024, then tumbled by 4314.73% to 1.45 in 2025.
• The last three Equity Ratio figures came in at 1.45 (Q4 2025), 0.03 (Q4 2024), and 175947.42 (Q2 2024), per Business Quant data.